Warburg Pincus buys Mumbai’s pharma company Integrace in Rs 1,200 crore deal

In a landmark transaction, Warburg Pincus, a prominent US private equity firm, has purchased Integrace Private Limited for ₹1,200 crore. With this deal, True North and Temasek Holdings have decided to divest entirely from their stakes in the company. Rehan Khan, a seasoned leader in the industry, will take the helm as CEO, steering Integrace's focus on its celebrated orthopedic and gynecological brands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bWKc1ym
via IFTTT

Read More

Jitendra Singh releases Rs 1,500 crore under third phase of Biomedical Research Career Programme

Union Minister Jitendra Singh released fifteen hundred crore rupees for the Biomedical Research Career Programme. This funding supports outstanding biomedical researchers and promotes collaborative research initiatives. The program, initiated in two thousand eight, has supported over five hundred researchers. It has also strengthened research across more than two hundred institutions nationwide.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JrUtK9b
via IFTTT

Read More

Warburg Pincus buys Mumbai’s pharma company Integrace in ₹1,200 crore deal

In a landmark transaction, Warburg Pincus, a prominent US private equity firm, has purchased Integrace Private Limited for ₹1,200 crore. With this deal, True North and Temasek Holdings have decided to divest entirely from their stakes in the company. Rehan Khan, a seasoned leader in the industry, will take the helm as CEO, steering Integrace's focus on its celebrated orthopedic and gynecological brands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xiPgYI4
via IFTTT

Read More

Sun Pharma gets SAHPRA approval for generic semaglutide injection in South Africa for type 2 diabetes

South Africa's regulator approved Sun Pharma's generic semaglutide injection for diabetes. This approval allows marketing to supplement diet and exercise for adults. The company plans to launch the product soon in injectable pens. South Africa is the second market after India for this approval. This reflects Sun Pharma's commitment to improving access to generics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/S7kuYoN
via IFTTT

Read More

OneSource Specialty Pharma partners with Formycon AG to manufacture biosimilars

OneSource Specialty Pharma has announced a manufacturing partnership for biosimilars with Formycon AG. This collaboration will see OneSource providing integrated manufacturing capabilities for biosimilars. The partnership aims to expand access to high-quality, affordable biologics for patients globally. Formycon AG CEO stated this strengthens their supply capabilities with a quality-focused partner. Both companies aim to broaden sustainable global access to life-changing biosimilar therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EtkJz94
via IFTTT

Read More

FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug

The US FDA approved an at-home starting dose for Eisai and Biogen's Alzheimer's drug. This new subcutaneous formulation allows patients to self-administer injections, improving access. Previously, patients received intravenous infusions, typically at clinics, for initial treatment. This approval differentiates Leqembi from competitor Kisunla's infusion-only requirement. The drug targets amyloid beta plaques in the brains of Alzheimer's patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oj2OFg0
via IFTTT

Read More

Warburg, Bain, CVC among PE firms in talks to buy into Agappe Diagnostics

Several global private equity firms are exploring a significant stake purchase in Agappe Diagnostics. This potential deal involves both existing investor sales and new capital infusion. The transaction is expected to value the Kochi-based in-vitro diagnostics firm at over three thousand crore rupees. Agappe Diagnostics develops and manufactures diagnostic reagents and equipment for global markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GAwaOnq
via IFTTT

Read More

Emcure buys remaining 12.05% in Gennova to take full control

Emcure Pharma is acquiring the remaining stake in Gennova Biopharmaceuticals. This move simplifies ownership and sharpens strategic focus for the subsidiary. Gennova will now be led by Samit Mehta for its next growth phase. The company will continue leveraging its biomanufacturing platforms for new products. Gennova's former CEO Sanjay Singh has divested its mRNA business.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VYAtfO9
via IFTTT

Read More

First vaccine for Bundibugyo Ebola hits human trials in Oxford study

Oxford's Ebola vaccine candidate has entered Phase 1 clinical trials for safety evaluation. The ChAdOx1 BDBV vaccine uses a platform similar to the Covid-19 vaccine. Serum Institute of India manufactured approximately 620,000 doses for potential future use. This initiative builds on a strategic partnership with CEPI and the University of Oxford. Late-stage trials will follow if Phase 1 results prove successful.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ykevW63
via IFTTT

Read More

Schedule H1 explained: Why did India tighten its prescription rules for high-alcohol medicines?

Schedule H1 Explained: High-alcohol oral medicines now require a doctor's prescription under Schedule H1. This stricter classification mandates detailed sales records for pharmacies. The government aims to prevent misuse and diversion of these potent preparations. Previously exempt alcohol-based tonics face new licensing and prescription rules. Patients will need valid prescriptions for these medicines moving forward.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Y318qeg
via IFTTT

Read More

Pharma body renews push for data protection

Leading pharmaceutical companies seek Regulatory Data Protection to boost research investments. Public health groups and local makers oppose this, fearing extended monopolies and delayed generics. The Organization of Pharmaceutical Producers of India argues it benefits indigenous drug makers too. China has already implemented similar clauses, seeing significant research deal growth. India's regulatory alignment with global practices could attract discovery research investments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RGLQobI
via IFTTT

Read More

Antibiotic resistance emerging as major threat to surgical care: Experts

Antimicrobial resistance now challenges routine surgical procedures and increases infection risks. Surgeons warn that losing effective antibiotics undermines decades of progress in safe surgery. Hospitals are adopting stricter antibiotic stewardship and infection prevention measures. Multidrug-resistant organisms pose a significant challenge to treating post-operative infections effectively. Preserving antibiotic effectiveness is a shared responsibility for future generations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1wU9h0H
via IFTTT

Read More

Maharashtra FDA bars sale of two Cadila drugs over branding concerns

Maharashtra FDA has seized Cadila Pharmaceuticals drug stock worth Rs 2.45 crore. The action was taken due to similar branding on different active ingredients. Officials barred sales of Aciloc 150 Plus and Aciloc 300 Plus medicines. This move aims to prevent medication errors and safeguard public health. Further investigation and legal action are currently underway.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JnbCdmg
via IFTTT

Read More

Medicines with over 12% alcohol can no longer be sold without prescription: Govt

In a new regulatory change, medications with alcohol content exceeding twelve percent will require a prescription from a doctor. This decision treats these products like standard prescription drugs, compelling manufacturers to obtain the necessary licenses. Furthermore, pharmacies are now tasked with rigorous record-keeping to mitigate potential abuse and ensure that genuine medical use is preserved under enhanced scrutiny.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KFcNM9Q
via IFTTT

Read More

Dr Reddy’s pauses weight loss drug on quality fears

Dr Reddy's Laboratories will halt semaglutide injection supplies until at least October. Unspecified impurities were identified during the active pharmaceutical ingredient manufacturing scale-up. The company assures that already supplied market products remain safe for patient use. Torrent Pharmaceuticals and USV Ltd are recalling some semaglutide batches sourced from Dr Reddy's. Commercial supplies are expected to resume after the issue is resolved and validation is complete.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dwmf6Hl
via IFTTT

Read More

GA-Renova & CCA in race to buy American oncology: Siemens Healthineers looking to exit non-core business for Rs 1,500 crore

Two prominent players are in the running to purchase American Oncology Institute from Siemens Healthineers. One of the potential buyers is General Atlantic in collaboration with Renova Hospitals, while the other contender is Raj Mantena's Cancer Centers of America. Siemens Healthineers initially acquired this cancer network as part of a larger strategic agreement. The completion of the sale is anticipated by mid-August.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SNcbioP
via IFTTT

Read More

Dr Reddy's flags quality issue in semaglutide batches, delays commercial supplies

Dr Reddy's Laboratories has announced a setback in the distribution of their semaglutide products attributed to out-of-specification batches associated with an active ingredient concern. The firm is actively investigating to identify the source of the problem and is implementing corrective strategies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0z2tmvd
via IFTTT

Read More

Novo Nordisk readies once-a-week insulin shot for Indian market

Novo Nordisk is set to introduce Awiqli, an innovative once-weekly insulin, in India shortly. This remarkable treatment drastically cuts down the number of insulin injections from 365 annually to only 52. Awiqli could redefine the approach to diabetes management, offering promising cost savings compared to existing therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ChAb7oH
via IFTTT

Read More

Cultural sensitivity, communication key to strengthening India's medical tourism appeal: IIM experts

Experts highlight cultural sensitivity and communication's importance for international medical tourists. Effective expectation management and communication enhance patient experiences in Indian hospitals. India is a leading medical tourism destination due to advanced healthcare and affordable costs. Hospitals should invest in intercultural communication training for professionals. Bridging cultural gaps improves patient satisfaction and India's market competitiveness.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OCSImb8
via IFTTT

Read More

Navi Mumbai Airport notified as port for import of drugs under Drugs Rules

Navi Mumbai Airport has been designated as a port for drug imports, a decision that boosts the pharmaceutical supply chain and simplifies trade activities. Following the amendment to Drugs Rules, 1945, the total number of notified ports has increased to 42. This initiative is aimed at facilitating efficient movement of pharmaceutical goods and enhancing regulatory oversight, showcasing the government's dedication to improving trade dynamics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AWFJEtN
via IFTTT

Read More

Regulator seeks views to curb similar sounding drug brands

The Central Drugs Standard Control Organisation in India is inviting public contributions concerning new regulations aimed at curbing the sale of various medications under similar brand names, which can mislead both patients and pharmacists about their contents. As part of this initiative, the drug regulator has released a notice for stakeholder observations, with a deadline for comments set for July 17 to ensure improved safety and trust among patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nTO3oJP
via IFTTT

Read More

India's wellness industry poised for growth amid focus on preventive healthcare, rising income: EBG Group chief

India's wellness market, valued at over $150 billion, is set for growth fueled by rising health consciousness and disposable incomes. EBG Group is launching Carlton Wellness India, an integrated ecosystem blending traditional Indian healing with modern hospitality. This platform will offer diverse wellness experiences, from city centers to retreats, emphasizing preventive care and holistic wellbeing for everyday life.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WPFLkpU
via IFTTT

Read More

Gene therapy firm Immuneel ties up with Arogya Finance to offer Rs 25 lakh zero-cost EMI for cancer treatment

Immuneel Therapeutics collaborates with Arogya Finance to unveil a zero-cost EMI scheme for advanced cancer treatments, providing support of up to Rs 25 lakh. This effort is a segment of Immuneel's Saksham Patient Access Program, letting eligible patients benefit from interest-free installments for as long as 12 months, thereby reducing financial pressures and facilitating prompt access to essential therapies for those in need.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9GLTgKS
via IFTTT

Read More

Glenmark launches generic Olanzapine injection in US

Glenmark Pharmaceuticals has launched a generic version of Olanzapine injection in the United States, offering a treatment for schizophrenia and bipolar disorder. This move by its US arm, Glenmark Pharmaceuticals Inc., introduces a bioequivalent alternative to Zyprexa intramuscular injection. The company aims to expand its injectable offerings and bolster its presence in the institutional market, targeting a segment with significant annual sales.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cZKjp6i
via IFTTT

Read More

Death in a vial: Five cases lay bare many uncomfortable truths about Indian healthcare

Five young mothers in Kota died after childbirth, with suspicion falling on oxytocin injections. Investigations revealed the vials contained only water, not the active ingredient. The manufacturer, Jackson Laboratories, has had stop-production orders earlier as well. This incident has put focus on critical failures in drug regulation and raises serious concerns about patient safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iaItPh9
via IFTTT

Read More

Adani Group to set up 2,000-bed hospital in New Town: Bengal CM

West Bengal Chief Minister Suvendu Adhikari announced that the Adani Group will establish a 2,000-bed hospital in New Town. A significant portion, 1,000 beds, will be dedicated to providing free treatment for the underprivileged. The remaining beds will be utilized for commercial operations. This initiative was revealed during an interaction with civil society members, highlighting the government's recent efforts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MkG8EVN
via IFTTT

Read More

OnCare launches cancer treatment centre in Bengaluru

Bengaluru now has a new cancer treatment centre launched by OnCare, aiming to bring accessible, affordable, and patient-friendly oncology services to the region. Following success in Delhi-NCR, the facility offers comprehensive care including chemotherapy, immunotherapy, and supportive services.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4oBSebW
via IFTTT

Read More

Fortis Healthcare inks pact with Dion Group for 300-bed hospital in Cuttack

Fortis Healthcare is set to manage and operate a new 300-bed multi-specialty hospital in Cuttack, Odisha, a project valued at Rs 600 crore. Developed by Dion Group, the facility aims to significantly enhance access to advanced tertiary care for residents of Cuttack, Bhubaneswar, and surrounding areas. This collaboration merges Fortis's extensive healthcare expertise with Dion's infrastructure development vision, promising quality medical services closer to home.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mTuJNxy
via IFTTT

Read More

Sun Pharma secures relief in 'Pantocid' trademark dispute

Delhi High Court has halted Ahmedabad-based Finecure Pharmaceuticals from producing and selling drugs with names similar to Sun Pharma's 'Pantocid'. The court permitted Finecure to sell existing stock of 'Pantopacid' within four months, provided an affidavit detailing the inventory is filed. This decision overturns a previous ruling that had refused to grant an injunction against Finecure, highlighting significant sales disparities between the two companies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/j2dpVz7
via IFTTT

Read More

Syngene International MD & CEO Peter Bains resigns

Bains has resigned from the position of MD & CEO with effect from the close of business hours on June 30, Syngene International said in a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YdApZaN
via IFTTT

Read More

Zydus Lifesciences ties up with Apollo Hospitals to offer Shield multi-cancer detection test

Zydus Lifesciences has partnered with Apollo Hospitals to introduce the Shield multi-cancer detection test in India, made possible through an agreement with Guardant Health. This innovative blood test can identify signals for multiple cancer types in individuals aged 45 and above. The collaboration aims to enhance early cancer detection and improve patient outcomes across the nation, making advanced screening more accessible.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7sBNd9h
via IFTTT

Read More

New rules simplify drug launches, reduce manufacturer liability for overcharging

New rules now allow drug manufacturers to launch similar medicines without prior price approval, streamlining market entry. Companies can seek varied prices for drug variants based on packaging and dosage, fostering flexibility. Overcharging liability is now limited to specific distributors if manufacturers prove compliance, easing burdens for many firms. Stricter record-keeping for seven years is also mandated.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ciaZRXt
via IFTTT

Read More

Shantha Biologics to make injectable drug cartridges for Novo Nordisk

Shantha Biologics has secured a significant contract with Danish pharmaceutical giant Novo Nordisk to manufacture cartridges for injectable medicines at its Hyderabad facility. This partnership highlights India's growing role in advanced pharmaceutical manufacturing, particularly for high-demand diabetes and obesity therapies. Shantha's FDA-approved, automated fill-finish lines will produce these critical components, underscoring the company's expanding capabilities in contract manufacturing for biologics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eqmNj5D
via IFTTT

Read More

Generics must not be imperiled over data protection: Satish Reddy, Chairman, Dr Reddy's Laboratories

Dr Reddy's chairman, Satish Reddy, has raised concerns about compromising India's competitive edge in generics for foreign investments. He stresses the importance of aligning capital with developmental needs and enhancing collaboration between academia and industry. Advocating for a national mission akin to China's, he highlights the necessity of structured government procurement to stimulate drug innovation and underscores AI's transformative role in drug discovery, contingent on adaptive regulatory systems.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Zy56Brh
via IFTTT

Read More

Telangana bets big on drug discovery hub

Telangana is gearing up to elevate Hyderabad's pharmaceutical standing beyond manufacturing. The state is fostering an integrated ecosystem for drug discovery and development, bringing together industry, research, startups, and investors. This strategic move aims to position Telangana as a hub for next-generation therapies, leveraging its existing strength as a global vaccine production leader.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O9uben6
via IFTTT

Read More

Mankind Pharma partners Denovo Sciences for AI-led drug discovery

Mankind Pharma has partnered with Denovo Sciences to accelerate drug discovery using artificial intelligence. This collaboration aims to significantly cut down early research timelines, enhance the quality of potential drug candidates, and ensure only the most promising ones advance. By combining Mankind Pharma's R&D prowess with Denovo's AI platform, the companies expect to bring effective and accessible treatments to patients faster, marking a significant step in innovation-driven research.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GtiF5H8
via IFTTT

Read More

mRNA vaccines protect against severe infectious diseases, review confirms

Billions of mRNA vaccine doses administered globally confirm their safety and effectiveness against infectious diseases, including severe COVID-19, across all age groups and health conditions. Researchers emphasize that serious side effects are rare, with benefits far outweighing risks. This technology, now proven, holds immense promise for future vaccines and personalized treatments, though equitable global access remains crucial.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZiMdsJ0
via IFTTT

Read More

Mankind Pharma joins hands with Denovo Sciences for AI-powered drug discovery

Mankind Pharma has joined forces with Denovo Sciences to revolutionize drug discovery using artificial intelligence. This strategic partnership aims to significantly shorten development timelines, improve the quality of potential drug candidates, and identify the most promising options. By integrating AI with human expertise, the companies are set to accelerate the delivery of effective and accessible new medicines to patients, marking a significant step forward in pharmaceutical innovation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oHUbqxj
via IFTTT

Read More

Telangana plans drug discovery push to move Hyderabad up pharma value chain

Telangana is charting a new course to elevate Hyderabad into a global drug discovery hub. The state is fostering an integrated ecosystem by creating shared infrastructure and funding for startups and researchers. This ambitious plan aims to accelerate the development of next-generation therapies, including cell and gene therapies, by leveraging existing strengths and forging new partnerships, positioning Hyderabad for significant advancements in pharmaceutical innovation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Sxoj2Tm
via IFTTT

Read More

Alembic Pharmaceuticals gets USFDA nod for generic acne treatment gel

Alembic Pharmaceuticals has secured final USFDA approval for its generic Dapsone gel, a topical treatment for acne vulgaris. This approval, for the 5% strength, means the company can now market its version, which is therapeutically equivalent to Almirall's Aczone Gel. This development marks a significant step for Alembic in the US market, offering a new option for acne sufferers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nMls3jE
via IFTTT

Read More

India’s nutraceutical market set to nearly double to $57 billion by 2030 on preventive health boom

India's health-conscious population is fueling a boom in the nutraceutical market, projected to nearly double to $55-57 billion by 2030. This shift towards preventive care, supported by e-commerce and government initiatives, sees the sector growing at an impressive 10.5% CAGR. While regulatory efforts are strengthening, challenges like consumer awareness and scientific validation persist, yet the industry is poised for significant expansion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Na4JrkL
via IFTTT

Read More

Health ministry proposes faster approvals for medical device manufacturing licences

The Union health ministry is proposing to significantly cut down the time taken to issue manufacturing licenses for medical devices. Aimed at boosting ease of doing business and ensuring quicker access to quality products, the amendments will reduce timelines for low to high-risk devices. For instance, Class B devices will see a reduction from 140 to 115 days, and high-risk Class C and D devices from 105 to 90 days.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O2VZyaD
via IFTTT

Read More

Strides Pharma sells majority stake in arm Pivot Path for Rs 100 crore

Strides Pharma Science has divested a majority stake in its subsidiary, Pivot Path, for Rs 100 crore to a consortium led by Ascent Capital and Vintage Classic. This strategic move aims to accelerate Pivot Path's growth by infusing Rs 50 crore for future expansion. Strides will retain a 19.95% stake, while the investors will hold 65.05%. The transaction values Pivot Path at Rs 230 crore post-money.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Th4cZFf
via IFTTT

Read More

Shelf-life norms for imported drugs may be relaxed to reduce wastage

India is set to revise rules for imported medicines, proposing a 12-month minimum residual shelf life instead of the current 60% rule. This aims to ease business and reduce wastage, particularly for drugs with longer expiry dates. However, biological and radiopharmaceutical products will retain the stricter 60% requirement due to public health concerns. Other quality and safety regulations remain unchanged.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wThKdeR
via IFTTT

Read More

Centre set to tighten oversight of pharma packaging materials

India is set to implement a mandatory registration for printed pharmaceutical packaging manufacturers to combat counterfeit drugs. This move follows seizures of fake weight-loss drugs and vaccines, revealing that genuine packaging materials were being diverted and misused abroad.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jsBbCfL
via IFTTT

Read More

India's GLP-1 boom slows amid price war, weak retention

Initial excitement for India's generic weight-loss drugs is fading. Domestic manufacturers are lowering sales targets due to slower-than-expected prescriptions and patient retention. Unexpected price cuts from the innovator, coupled with the high cost of generics for Indian consumers, are impacting adoption. This has led to a wait-and-watch approach for upcoming launches, with a potential revival anticipated later in the fiscal year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5kmvBXf
via IFTTT

Read More

Eli Lilly launches cancer drug Tanstrive in India

The launch follows marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for patients with locally advanced or metastatic solid tumours with a rearranged during transfection (RET) gene, the company said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IZDaN69
via IFTTT

Read More

NITI Aayog proposes pharma chapter for future FTAs, urges India to move up value chain

Niti Aayog proposes a blueprint for free trade agreements to boost regulatory predictability in India's pharmaceutical sector. The think tank urges a shift towards high-value segments, emphasizing enhanced industry-academia collaboration for patent commercialization and startup incubation. While India is the 'pharmacy of the world,' it needs to move up the value chain by focusing on deeptech innovation to become a capital for pharma innovation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Blf4C3J
via IFTTT

Read More

India's pharma supply chain remains 65 per cent dependent on China for critical inputs: NITI Aayog

India's pharmaceutical sector, despite being the "pharmacy of the world," faces significant reliance on China for raw materials, with nearly 65% of APIs and intermediates sourced from there. NITI Aayog's report highlights supply chain vulnerabilities and calls for moving up the value chain by fostering innovation and industry-academia collaboration. This strategic shift aims to boost high-value product development and capture a larger global market share.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pPlx4t3
via IFTTT

Read More

Healthium Medtech CEO Anish Bafna steps down, moves to non-executive chairman role

Healthium Medtech's CEO Anish Bafna is transitioning to non-executive chairman as KKR-owned company seeks a new chief within a month. Bafna, instrumental in Healthium's growth and acquisitions since 2018, will aid in successor selection. Despite record revenue, the medical devices firm saw profits decline recently, facing market competition and a slowdown in the Indian surgical products sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Y0Fua5X
via IFTTT

Read More

Stress, poor sleep and processed food are driving heart attacks in young Indians: Ramakanta Panda

Young Indian professionals, particularly in IT and finance, are facing a heart disease crisis due to unhealthy lifestyles. Leading cardiac surgeon Dr. Ramakanta Panda highlights chronic stress, poor sleep, processed foods, and sedentary habits as major culprits behind a surge in heart attacks among those in their 30s and 40s.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Fy2aELA
via IFTTT

Read More

Central Drugs Laboratories find 46 drug samples not of standard quality for May

Health officials revealed that in May 2026, 46 drug samples tested by Central Drugs Laboratories and 113 by State Drugs Testing Laboratories were found to be of substandard quality. Additionally, one spurious drug, manufactured by an unauthorized entity using another company's brand, was identified in Assam and is under investigation. These findings highlight ongoing efforts to ensure drug safety and remove substandard products from circulation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/F2gpiGV
via IFTTT

Read More

Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett Company

Aurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic move, expected to conclude by June 2026, will bolster Aurobindo's complex generics and controlled substances portfolio, enhance its US manufacturing capabilities with Lannett's Indiana facility, and is projected to immediately boost earnings per share.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qi42rVf
via IFTTT

Read More

Jyothy Labs to expand Exo into broader dishwash franchise after Henkel brands exit portfolio

Jyothy Labs is strategically expanding its Exo dishwash brand into a comprehensive franchise following Henkel's exit from Pril and Fa licensing in India. The company remains cautiously optimistic about FY27 growth, focusing on premium products, innovation, and wider distribution despite inflationary pressures. New Exo variants are showing promising consumer response, aiming to boost sales and market share.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NH5MPcp
via IFTTT

Read More

Scanning cancer, up close & personal: A revolution is underway in cancer diagnosis

A gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Since the NGS test can be beyond the reach of many, a unique collaboration called LuNGS Alliance is making it free for lung cancer patients in India, offering a glimpse of how medical breakthroughs can be made accessible and affordable.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tjgNuyO
via IFTTT

Read More

Sun Pharma adds Innovcare to its fold in Rs 271.2 crore all-cash transaction

India's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash deal. This strategic move aims to bolster Sun Pharma's product offerings. Innovcare, which markets pharmaceutical drugs, nutraceuticals, and cosmeceuticals, reported steady revenue growth in recent fiscal years. The transaction, expected to conclude by July 2026, is a significant step for Sun Pharma's expansion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x6BPKQN
via IFTTT

Read More

Yoga may boost cognition, reduce depression, aid gut health in early Alzheimer's: AIIMS study

A 12-week yoga program has shown promising results for individuals with mild Alzheimer's disease. Researchers at AIIMS, Delhi, observed significant improvements in cognitive function and mood, alongside a healthier gut microbiome. The study suggests yoga may help restore beneficial gut bacteria, potentially influencing the gut-brain axis and offering a valuable complementary therapy for early-stage Alzheimer's and mild cognitive impairment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xbKZrwE
via IFTTT

Read More

Plan in the works to let hospitals import med equipment directly

India's drug regulator is proposing to allow hospitals to directly import advanced medical equipment like MRI and CT scanners, bypassing current import licenses. This move aims to speed up access to cutting-edge technology. However, the domestic medical device industry expresses concern, citing safety risks and the specialized expertise of licensed importers in handling high-risk equipment and ensuring quality.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iPEWgbe
via IFTTT

Read More

Societe General, Prudential, others buy 3 per cent stake in Anthem Biosciences for Rs 1,275 cr

Global investors including Societe Generale and Prudential Hong Kong, alongside Indian mutual funds and insurance companies, have bought a 3 percent stake in Anthem Biosciences. The deal, valued at Rs 1,275 crore, saw promoter Aruna Ganesh exit the company. This significant transaction reshapes the promoter's holding in the integrated Contract Research, Development and Manufacturing Organisation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/67R3r9I
via IFTTT

Read More

Aurobindo Pharma clears key US hurdle in Lannett acquisition, closing expected soon

Indian drug giant Aurobindo Pharma is set for a major US expansion. The company has received crucial antitrust clearance from the US Federal Trade Commission for its takeover of Lannett Company. This regulatory approval removes the final hurdle. The acquisition is expected to close by the end of June.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XzE6rDb
via IFTTT

Read More

HPV vaccination drive reaches 50 lakh girls in three months

India's free Human Papillomavirus vaccination drive is making significant progress. Nearly 50 lakh doses of the cervical cancer vaccine have been administered to 14-year-old girls. This initiative covers almost half of the 1.15 crore target population nationwide. Madhya Pradesh and Gujarat have already achieved 100% of their targets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/85l3uED
via IFTTT

Read More

US FTC imposes divestment condition on Aurobindo Pharma's $250 mn Lannett acquisition

The U.S. Federal Trade Commission (FTC) has mandated that Aurobindo Pharma must sell off four specific drug products. This action is a condition for Aurobindo Pharma to finalize its acquisition of Lannett Company Inc., ensuring no anti-competitive issues arise from the deal.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u3jUDq4
via IFTTT

Read More

KKR eyes at least $1 billion stake in Medicover's India hospital arm, source says

Global investment firm KKR is in advanced discussions to acquire a significant stake in Medicover's Indian hospital operations. The deal is valued at over one billion dollars. Medicover, a Swedish healthcare group, confirmed these talks. This potential acquisition marks a substantial expansion for KKR in India's growing healthcare sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sc8UvWY
via IFTTT

Read More

API prices fall as West Asia tensions ease, boosting Indian pharma sector

Prices for active pharmaceutical ingredients have seen a decline of five to ten percent, thanks to the calming geopolitical climate in West Asia, which has brought stability to supply chains. Indian pharmaceutical manufacturers are breathing a sigh of relief as they manage to offset rising input expenses.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9PFqER2
via IFTTT

Read More

Public-private projects key to expand access to Kidney care: NephroPlus

NephroPlus, India's leading provider of dialysis services, is on a mission to reshape the future of kidney health with an innovative tech-based platform aimed at preventing chronic kidney disease. As it scales up its network of dialysis centers both domestically and in global markets, this forward-thinking initiative seeks to combat the advancement of kidney ailments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Wwvfs57
via IFTTT

Read More

Government prescribes end to over-the-counter sale of cough syrups

Even in small villages with a population of less than 1,000, where certain remedies including cough syrups were allowed to be sold without retail sale licences so far, now only duly licensed pharmacies can dispense cough syrups.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1URFfBh
via IFTTT

Read More

Cloudnine's 25% stake sale attracts top global PE firms

Leading global private equity firms are in the running to acquire a substantial minority stake in Cloudnine, India's premier maternity and paediatric hospital chain. The deal is expected to value the company at approximately $1.2 billion. This strategic move will see existing investor True North exit, while other shareholders are likely to retain their positions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hou2fNW
via IFTTT

Read More

Zydus Lifesciences completes acquisition of Assertio

The company has successfully completed the cash tender offer, through wholly-owned subsidiary, Zara Merger Sub Inc, for all the outstanding shares of common stock of Assertio Holdings Inc, Zydus Lifesciences said in a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HWTdaGt
via IFTTT

Read More

Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for Biocon

Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalizing on growing demand as major pharmaceutical companies shift focus to newer weight-loss drugs. Currently the third-largest global insulin provider, Biocon is significantly expanding production. This strategic move addresses a critical gap in the market, particularly in emerging economies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7cvhk2i
via IFTTT

Read More

Your shampoo may be cleaning your hair, but is it treating your scalp?

Most shampoos do a decent job of cleaning the hair shaft. But if you keep dealing with flakes, an itchy scalp, or that persistent oily feeling, the problem likely isn't your hair. It's what's happening underneath.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gGRMwAE
via IFTTT

Read More

Apollo Hospitals taps Shobana Kamineni to chair soon-to-be listed Healthtech unit

Apollo Hospitals is appointing Shobana Kamineni as executive chairperson of its upcoming medical equipment business, Apollo Healthtech. This move is part of a larger restructuring plan to unlock business value. Apollo Healthtech is expected to be listed separately. The company aims for significant revenue by listing. This signals a focus on growth and governance for the new entity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0Rbf8iQ
via IFTTT

Read More

Novartis India launches Pluvicto for prostate cancer treatment

Novartis India has launched Pluvicto, the nation's first approved radioligand therapy for eligible prostate cancer patients. This precision radiotherapy precisely targets cancer cells, offering a new treatment approach for metastatic prostate cancer. The therapy will be available through select hospitals and nuclear medicine centers across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/f1EnHrB
via IFTTT

Read More

India known as nation with world's largest healthcare programme: PM Modi

Prime Minister Narendra Modi said India has made healthcare more affordable and accessible over the past 12 years through initiatives such as Ayushman Bharat and the PM Bharatiya Jan Aushadhi Pariyojana. He highlighted lower-cost medicines and medical devices, expanded medical education, and progress in tackling diseases like tuberculosis.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/b0K2LuN
via IFTTT

Read More

Maharashtra FDA bars hospitals from forcing patients to buy medicines in-house

Maharashtra's Food and Drug Administration has issued a significant directive. Hospitals and medical practitioners must now allow patients to purchase medicines from any licensed pharmacy. Patients will receive their prescriptions directly. This move aims to prevent unfair trade practices and protect patient consumer rights.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/htfYjdp
via IFTTT

Read More

Eli Lilly's Alzheimer's drug donanemab approved in India, but neurologists flag cost, access barriers

A new drug for Alzheimer's, donanemab, has arrived in India. It aims to slow the disease's progression by clearing brain plaques. While offering potential benefits, experts highlight concerns about its high cost and the need for early diagnosis. The drug's real-world impact in India remains a subject of discussion among neurologists and the company.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Mp3YCOg
via IFTTT

Read More

India raises price cap on cancer drugs to tackle shortage

India's drug price regulator has increased the ceiling prices of cancer drugs cisplatin and carboplatin by 50% to tackle shortages caused by a sharp rise in platinum costs. The National Pharmaceutical Pricing Authority (NPPA) approved the one-time hike in public interest after supply disruptions affected hospitals across the country.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fkU3Y9y
via IFTTT

Read More

UK approves Novo weight-loss pill to edge open European market

Britain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatment. Over 10 million people with obesity in the UK now have an alternative to injections. Drugmakers are racing to expand use of these transformative medicines. The market is expected to reach over 100 billion dollars by 2030.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Qb8KzFm
via IFTTT

Read More

Regulators tighten GMP oversight of pharma plants

Several states have constituted dedicated multi-member teams to ensure no facility slips through the cracks before a GMP Certificate is issued, people in the know told ET. The inspections will now be applicable to all manufacturing units without exception including MSMEs, which had previously been granted a relaxation period that lapsed in January.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nCWQ6U1
via IFTTT

Read More

India needs to remain attractive for innovation-led investment: Judith Love, Novartis

With an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The company underscores the importance of collaboration to tackle obstacles like high costs and inadequate infrastructure.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GP6dNjY
via IFTTT

Read More

US drug regulator issues import alert for drugs made at a Dabur India plant

The US Food and Drug Administration has placed Dabur India's factory on an import alert. This action follows an inspection that revealed significant issues with data integrity and factory maintenance. Critical manufacturing records were reportedly falsified. Live birds and droppings were also found in a raw material warehouse.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Pa87rF2
via IFTTT

Read More

AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancer

AstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its import, sale, and distribution for an additional use. The drug will now be available as a first-line treatment for certain types of advanced breast cancer. This development expands treatment options for oncologists and patients facing HER2-positive breast cancer.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Wg9noPJ
via IFTTT

Read More

Government may lift price cap on cancer drugs making them costlier by up to 50%

India's government is taking emergency steps to ensure cancer patients get vital drugs. Cisplatin and carboplatin, crucial chemotherapy agents, faced shortages due to rising raw material costs. The government may allow significant price increases to boost production. This move aims to prevent treatment disruptions for thousands of patients across the nation. Revised prices are expected soon.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TVo6ZdO
via IFTTT

Read More

India's healthcare transformed in 12 years under PM Modi: Report

India's healthcare sector has seen a major transformation over the last 12 years. Health insurance coverage has expanded significantly. Maternal and child healthcare has improved. Medical infrastructure has seen a substantial increase. The government has focused on making healthcare accessible and affordable for all citizens.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JnAVjwk
via IFTTT

Read More

Hetero partners with Richter to develop, market Semaglutide injection globally

Hyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic of Ozempic. This collaboration aims to expand global access to diabetes therapies. Regulatory filings are underway, with EU and US submissions planned for 2027. The partnership leverages Hetero's market presence and Richter's European network.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Xtu7rKd
via IFTTT

Read More

Insider trading: Supreme Court upholds SAT clearance to Biocon MD

The Supreme Court has backed a tribunal's decision, clearing Biocon's managing director, Shreehas P Tambe, of insider trading allegations from 2017. The Securities and Exchange Board of India's appeal was rejected. Tambe was accused of trading Biocon shares while possessing unpublished price-sensitive information.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/z6uFayf
via IFTTT

Read More

SBI in $1 billion funding for Sun Pharma’s US deal

State Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co. This move marks a significant step for government-run banks in financing corporate takeovers. SBI will join other global lenders in this substantial deal. The funding underscores the growing ambition of Indian companies to expand globally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tFWdJlE
via IFTTT

Read More

Indian cancer patients battle shortage of key drugs as platinum costs surge

Cancer patients in India are struggling to find essential platinum-based drugs. A surge in global platinum prices and supply chain issues are causing shortages. This forces patients to search extensively for medication. Some drugmakers have reduced production. The situation puts immense pressure on the healthcare system and patients seeking treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/32DvEAG
via IFTTT

Read More

India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide sales

India's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moderating. Doctors note that physician training and patient education are now crucial for future market expansion. Meanwhile, tirzepatide shows a recovery, maintaining its market position. Competition remains intense with numerous semaglutide brands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9B16sJw
via IFTTT

Read More

India willing to open its market to high-quality, innovative pharma products, says commerce minister

India is ready to welcome high-quality global pharmaceutical products. This move is in exchange for better market access for Indian drug exports. The Indian pharma market is set to double in five years. Global companies are invited to invest in India's vast market and skilled workforce. India is a major supplier of generic medicines and vaccines worldwide.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yUNzlbi
via IFTTT

Read More

Uzbekistan can provide more incentives to Indian pharma firms, aims to become regional hub for supply

Uzbekistan is inviting Indian drug companies to invest more. They are offering better subsidies and technology help. This aims to make Uzbekistan a key hub for making and supplying medicines in the region. Simplified rules and tax benefits will encourage more investment. This move will boost local healthcare and strengthen trade ties between the two nations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hzZ18xB
via IFTTT

Read More

Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits

Eli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoarthritis pain in adults with obesity. Patients also experienced substantial weight loss. These findings were shared at an American Diabetes Association conference. Retatrutide targets multiple hormones related to obesity and diabetes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iIhEzGt
via IFTTT

Read More

Hospital expansion cycle to keep margins rangebound, but 18 per cent revenue growth trend likely to sustain: Kotak Securities

Indian hospitals are set for strong revenue growth. Brokerage firm Kotak Securities predicts double-digit gains. EBITDA margins are expected to remain stable. This outlook comes despite significant bed expansion. Hospital volumes and diagnostics are showing positive trends. The March quarter performance was robust, with sales and EBITDA growth reported. This indicates a healthy sector outlook for the coming period.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JCirLdg
via IFTTT

Read More

Regulator, cos discuss price hike for some cancer drugs

India's drug pricing authority may soon approve a price hike for vital platinum-based cancer medicines. These drugs, including carboplatin and cisplatin, are crucial for treating various cancers. The National Pharmaceutical Pricing Authority met with drug makers and hospital representatives to discuss the issue. Rising raw material costs have put pressure on production.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ebQqRAr
via IFTTT

Read More

Manipal Health takes Bengaluru hospital building on long-term lease

Manipal Health Enterprises has leased a 245,000-sq ft multi-speciality hospital in Bengaluru's Yelahanka for nearly 30 years, with an estimated total rental outgo of ₹816.1 crore. The lease agreement includes a starting monthly rent of ₹1.27 crore and a 10% rent escalation in the sixth year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PG2n5xB
via IFTTT

Read More

PE wars to billion-dollar IPO dreams, hospital sector is fighting fit

Major private equity firms are vying for a stake in Cloudnine, a leading maternity and paediatric care chain. This intense competition highlights strong investor confidence in India's healthcare sector. The industry is entering a new growth phase driven by increasing demand, a shortage of hospital beds, and a rise in specialized medical services.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/S3xQGYv
via IFTTT

Read More

Warburg, KKR, TPG among PE giants vying for 25% stake in Cloudnine

Global private equity giants, including Warburg Pincus and KKR, are vying for a 25% stake in India's largest maternity and pediatric hospital chain, Cloudnine. The deal is expected to value the company at approximately $1 billion, with existing investor True North exiting completely. Cloudnine reported revenues of ₹2,000 crore and EBITDA of ₹300 crore in FY26.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KIsAC3d
via IFTTT

Read More

Pharma exports to US seen muted this year

Indian pharma exports to the US face a subdued outlook this year. Policy uncertainties, falling generic prices, and regional conflicts are impacting shipments. US buyers are managing inventories more closely. A push for local manufacturing in the US also poses a challenge. This situation is creating caution among buyers for large forward orders.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/F3B7nNP
via IFTTT

Read More

Aurobindo Pharma enters biologics contract manufacturing with Rs 1,200-crore Telangana facility

Aurobindo Pharma has launched TheraNym, a major biologics manufacturing plant in Telangana. This facility will produce biologic medicines for global markets. US pharma giant MSD is the first major client. The plant signifies Aurobindo's expansion into the growing biologics and contract manufacturing sector. It is set to create over 1,500 jobs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EQ7zZbD
via IFTTT

Read More

Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concerns

The Delhi High Court has asked the Central Drugs Standard Control Organisation to review a petition challenging Zydus Lifesciences' approval for semaglutide injections. A diabetes patient raised concerns about the drug's delivery system, alleging it deviates from global standards and poses health risks. The court has directed the CDSCO to consider the patient's representation within two months.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IhibuV6
via IFTTT

Read More

Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight loss

Alkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordable for diabetes and obesity management. The company is the first in India to offer this convenient format. This move intensifies competition in the growing Indian drug market. Alkem aims to expand access to quality medicines for better patient care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZTqrRtK
via IFTTT

Read More

Serum Institute of India to manufacture Oxford Ebola vaccine backed by $8.6 million CEPI funding

Serum Institute of India will produce clinical trial doses of a new Ebola vaccine from Oxford University. This initiative is backed by fresh funding to combat a spreading outbreak in Africa. The vaccine uses technology similar to the Oxford-AstraZeneca Covid-19 vaccine. This partnership aims to accelerate development and ensure access for affected nations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZVmTMeO
via IFTTT

Read More

If you have the patience, you can achieve innovation milestones, says Wockhardt chairman Habil Khorakiwala

Wockhardt Hospitals is set to launch its antibiotic Zaynich in the US. Zahabiya Khorakiwala will lead US operations. The drug is expected to generate $1.5-2 billion in peak annual sales within 4-6 years. Wockhardt aims for a 20% share of the AMR market. The company is also developing new antibiotics for its pipeline.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RJinu2r
via IFTTT

Read More

GVK-backed Oval Fertility launched in Hyderabad, eyes share in India's growing IVF market

GVK family-backed Oval Fertility has launched its first premium IVF center in Hyderabad, leveraging advanced embryo monitoring technology. Co-founded by US fertility specialist Dr. Brian Levine and Veena Reddy, the venture aims to redefine fertility care with a blend of science, technology, and personalized patient experience. The clinic, priced at Rs 4.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NTjstYo
via IFTTT

Read More

FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics market

Wockhardt’s newly approved antibiotic Zaynich has the potential to transform the treatment of drug-resistant infections, according to Mahesh Patel, the scientist behind the drug. Approved by the US FDA for complicated urinary tract infections, Zaynich combines cefepime and zidebactam, using a novel “beta-lactam enhancer” mechanism that blocks two key steps in bacterial cell-wall synthesis, helping it overcome virtually all known resistance mechanisms.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cAJZxhe
via IFTTT

Read More

Novartis experimental actinium-based drug shows promise in prostate cancer treatment: Study

Novartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, even in patients who previously received Novartis' Pluvicto. Response rates were higher in patients without prior Pluvicto treatment. Larger trials are planned to assess side effects. Novartis is increasing its focus on radioligand therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/S8Y03QR
via IFTTT

Read More

Wockhardt secures US FDA approval for antibiotic Zaynich

Wockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. This breakthrough drug targets superbugs resistant to existing treatments. Zaynich also secured marketing authorization in India for similar infections and concurrent bacteremia, offering a significant solution to the growing threat of antimicrobial resistance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Mrkbf30
via IFTTT

Read More

Molecule glue drugs shake up cancer care, draw big money

Harvard-born idea doubles survival in trials, triggers pharma frenzy as cos race to target 'undruggable' proteins with next-gen glue therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/l5uhT37
via IFTTT

Read More

Lincoln Pharmaceuticals posts Rs 11.63 crore profit for Q4

Lincoln Pharmaceuticals announced a slight profit rise for the fourth quarter ending March 31, 2026. Full fiscal year 2025-26 saw over 6 percent growth in consolidated net profit. Revenue from operations also increased year-on-year. The company's board recommended an 18 percent dividend. Lincoln Pharmaceuticals targets Rs 1,000 crore revenue in three years.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/76Rj9yd
via IFTTT

Read More

Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEO

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to broaden its footprint in North America and Europe through sophisticated product offerings, Cipla is also intensifying its focus on managing chronic conditions such as diabetes and heart diseases in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6aAjqyO
via IFTTT

Read More

Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Goup CEO

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to broaden its footprint in North America and Europe through sophisticated product offerings, Cipla is also intensifying its focus on managing chronic conditions such as diabetes and heart diseases in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3WLvRrg
via IFTTT

Read More

Zydus Therapeutics' saroglitazar drug granted priority review by US FDA

Zydus Therapeutics' drug saroglitazar has received priority review from the US FDA. This drug treats primary biliary cholangitis, a liver disease. The company plans to launch saroglitazar in the US in the fourth quarter of fiscal year 2027.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gNGJ9PZ
via IFTTT

Read More

GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies

GSK's experimental hepatitis B drug, bepirovirsen, showed promising results in late-stage studies, with nearly one in five patients achieving a functional cure after six months of treatment. This offers a potential finite treatment course, a significant advancement over lifelong antiviral pills for the over 250 million people globally living with chronic hepatitis B.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T3KpX2D
via IFTTT

Read More

Wockhardt gets CDSCO nod for Zaynich antibiotic

Wockhardt Ltd has secured approval from the CDSCO for its new antibiotic, Zaynich. This drug is developed in India and will be used to treat complicated urinary tract infections in adults. The approval follows successful clinical trials. Zaynich shows potential against drug-resistant bacteria. This marks a significant step in combating challenging infections.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JLseqSv
via IFTTT

Read More

India's out-of-pocket healthcare spending drops significantly, govt data shows

Indian families now pay less for healthcare. Out-of-pocket spending fell from 64.2% to 43.4% in ten years. This is due to the government spending more on public health. Government health expenditure as a share of GDP has also increased. Per capita spending on health has grown significantly. This shows a stronger health financing safety net for citizens.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5kYMDTZ
via IFTTT

Read More

Gene therapy for cholesterol: Initial test results cheer

A new gene editing medicine, VERVE-102, offers hope for millions with heart conditions. Eli Lilly's drug showed significant reductions in bad cholesterol. This one-time infusion could transform heart disease management. Larger trials are planned, with a Phase II trial starting soon. This approach may eventually benefit broader populations at high cardiovascular risk.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/C6LDpzy
via IFTTT

Read More

Skymap Pharma to buy state-run Indian Medicines Pharma for Rs 121 crore

The inter-ministerial committee has officially sanctioned the acquisition of the Indian Medicines Pharmaceutical Corporation by Skymap Pharmaceuticals for a whopping ₹121 crore, securing a 100% ownership stake. This pivotal transaction marks the first strategic sell-off of a public sector entity in FY25, with the award letter now in circulation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZGuVTd5
via IFTTT

Read More

Government okays Skymap Pharmaceuticals' Rs 121-cr bid to buy IMPCL

The government has approved the sale of Indian Medicines Pharmaceutical Corporation Ltd. Skymap Pharmaceuticals Pvt Ltd will acquire the company for over Rs 121 crore. This strategic sale involves 100 percent stake and management control. IMPCL manufactures Ayurvedic and Unani medicines. The approval followed a competitive bidding process. The transaction is now being finalized.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DhAR0gZ
via IFTTT

Read More

Health services, medical education expansion to be driven by modern tech: Yogi Adityanath

Uttar Pradesh Chief Minister Yogi Adityanath reviewed health and medical education. He stressed improving treatment quality and expanding services. Medical colleges and nursing institutions will be strengthened with modern technology. Ayushman Yojana support for the poor was highlighted. Efforts are underway to enhance emergency services and control communicable diseases.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zD0yKUT
via IFTTT

Read More

India medical tourism market feels the weight of Iran war

India's medical tourism sector faces challenges as West Asian tensions continue. Overseas patient numbers remain lower than before the conflict intensified. Hospital chains report a gradual increase in inquiries and arrivals, but traffic has not fully recovered. Prolonged geopolitical uncertainty could also raise operating costs through inflation and currency fluctuations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fNZH7yg
via IFTTT

Read More

Park Medi World to acquire Medicity Hospital in Rudrapur, enter Uttarakhand

Hospital chain Park Medi World Limited is acquiring The Medicity Hospital in Rudrapur. The deal is valued at Rs 177 crore and is an all-cash transaction. This acquisition marks Park Group's entry into Uttarakhand. The Medicity Hospital is a multi-super speciality facility with 330 beds. This move aligns with the company's growth strategy to expand its network in underserved markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HeNUzh6
via IFTTT

Read More

Sakar Healthcare partners with Zydus Lifesciences for GCC Markets

Sakar Healthcare has partnered with Zydus Lifesciences to supply oncology products in GCC countries and other emerging markets. This marks the company's 40th global agreement in the anti-cancer segment. Sakar Healthcare is expanding its international oncology business and strengthening its presence in emerging markets. The company is also progressing with regulatory filings and approvals in highly regulated markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QytHJAx
via IFTTT

Read More

Kerala’s healthcare gold rush: How private equity is reshaping hospitals and raising fears over costs

Private equity funds are pouring hundreds of millions of dollars into Kerala’s healthcare sector, reshaping a system long dominated by independent doctors and family-run hospitals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/62xW7PU
via IFTTT

Read More

Venus Remedies gets Saudi FDA approval for speciality oncology therapy

Venus Remedies Limited has secured its first global marketing authorization for its specialty oncology therapy, Plerixafor, from the Saudi Food and Drug Authority (SFDA). This hematopoietic stem cell mobilizer is crucial for patients undergoing stem cell transplantation for multiple myeloma and non-Hodgkin lymphoma.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TFUKJvM
via IFTTT

Read More

Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration deal

Sun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. Significant progress is being made on the acquisition of Organon, with completion targeted for the last quarter of FY2027. This strategic move is set to enhance Sun Pharma's global presence and product portfolio across key therapeutic areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AWZO8sX
via IFTTT

Read More

Fortis liability case: Delhi HC says blame can't be shifted to third party

Amid ongoing legal disputes, the Delhi High Court is probing Fortis Healthcare's oversight concerning the sale of shares belonging to the Singh brothers, former promoters of the company. The court's remarks suggest that Fortis had a responsibility to inhibit such transactions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r02xIH5
via IFTTT

Read More

Invisalign maker Align Technology to invest Rs 1,800 crore in Hyderabad plant

US firm Align Technology will invest Rs 1,800 crore in Hyderabad for its first Indian manufacturing plant. This facility will be the company's fourth globally. It is expected to create over 300 jobs. The investment will boost Align Technology's existing operations in the city. The new plant will support its worldwide production of clear aligners.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BphLCdz
via IFTTT

Read More

Pregabalin moved to Schedule H1 as centre cracks down on drug misuse

Pregabalin, a nerve pain medication, now faces stricter controls. The Union health ministry has moved it to Schedule H1. This change aims to curb its misuse, especially among youth. Previously available over-the-counter, it now requires strict prescriptions. Pharmacies must maintain records and display prominent warnings.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Si5YHum
via IFTTT

Read More

ICMR replaces old system with single window approval for medical studies

The Indian Council of Medical Research has introduced a unified ethics approval process for multicentre medical studies, replacing the previous fragmented, site-by-site system. This significant reform aims to expedite research timelines, reduce costs, and expand participation to rural and vulnerable populations, fostering more representative and robust health policy evidence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KnMQj3G
via IFTTT

Read More

Eli Lilly’s obesity drug shows up to 30% weight loss in trial

Eli Lilly's new obesity drug retatrutide shows remarkable results. In a major trial, patients lost up to 30% of their body weight. This once-weekly injection targets multiple hormone receptors. The drug also improved heart health markers. Experts believe retatrutide could be a game-changer for treating obesity and improving patient health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FJEq4Sa
via IFTTT

Read More

No cosmetic job with jabs, warns drug regulator CDSCO

The notice issued by the Central Drugs Standard Control Organisation (CDSCO) cites provisions of the Drugs and Cosmetics Act, 1940, and the Cosmetics Rules, 2020.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QKycW0G
via IFTTT

Read More

India plans national registry to track implantable medical devices and patients

India is set to launch a national registry for implantable medical devices. This initiative aims to track all devices and patients, ensuring only certified products are used. The registry will help curb overuse and fix accountability. It will also aid in identifying patients during recalls and tracking real-world safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hDYFcAn
via IFTTT

Read More

Chemists’ strike: CDSCO moves to prevent shortages

The CDSCO has advised state drug controllers to prevent drug scarcity during the AIOCD's proposed e-pharmacy strike on May 20. Measures include ensuring pharmacies remain open, coordinating with police, and negotiating to keep some shops operational to avoid medicine deserts. The government emphasizes uninterrupted public access to medicines as a top priority.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uMGf1Jj
via IFTTT

Read More

NCLAT allows Lyka Labs appeal; asks Modi Lifecare to pay Rs 63 lakh or face insolvency proceedings

The NCLAT has ruled in favor of Lyka Labs. It overturned a previous NCLT decision. Modi Lifecare Industries must now pay Rs 63 lakh within 30 days. Failure to pay will lead to insolvency proceedings against the company. The tribunal found that Modi Lifecare acknowledged its debt. This ruling stems from unpaid royalties under a technical guidance agreement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xt5aeV0
via IFTTT

Read More

Hearzap to acquire Amplifon India, expand network to 420 hearing care centres

Hearzap is acquiring Amplifon India in a deal that will significantly expand the company's presence across the country. The combined entity will operate approximately 420 hearing care centers. With this move, Hearzap is seeking to strengthen position in the organised hearing care market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XzVcGMp
via IFTTT

Read More

Rising input costs, export slump take a toll on drug companies' health

India's drug makers are facing a double blow. A weaker rupee makes imported raw materials more expensive. Global economic worries are also slowing down demand for Indian medicines abroad. This is squeezing profits for manufacturers. Companies are trying to focus on more profitable products. The situation presents a tough operating environment for the industry.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UQdLPIH
via IFTTT

Read More

AbbVie loses patent plea for Hep C drug

The Indian Patent Office has denied a secondary patent for AbbVie's Hepatitis C drug Maviret. This decision ensures continued access to affordable treatment for millions. The patent office refused the application after AbbVie failed to contest oppositions and chose to abandon it. This refusal prevents AbbVie from extending its patent monopoly by five years.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NztJA5p
via IFTTT

Read More

Pharmacy associations to skip strike, major medicine disruption unlikely

A planned nationwide pharmacy strike on May 20 is unlikely to occur. Many retail pharmacy associations have withdrawn support. This follows assurances from the Central Drugs Standard Control Organisation that concerns about e-pharmacies are under review. Public interest and patient welfare are cited as reasons for declining the strike. Medicine availability is expected to remain uninterrupted.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pHjOo03
via IFTTT

Read More

Athena opens northeast India’s largest integrated psychiatric hospital in Guwahati

Athena Behavioral Health opens Northeast India's largest private psychiatric hospital in Guwahati. This marks their fifth hospital nationwide. The facility offers integrated treatment for mental health and substance use disorders. It aims to address the region's growing needs and shortage of structured care. The launch signifies a crucial step in making quality mental healthcare accessible in underserved areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wKiVf3e
via IFTTT

Read More

Dr Reddy’s launches generic Semaglutide injection, popular weight-loss drug, in Canada

Dr Reddy's Laboratories has launched its generic Semaglutide injection in Canada. This marks a significant step for the company in providing treatment for type 2 diabetes. Canada is the first G7 nation to approve this medication. The launch follows a recent introduction in India. Dr Reddy's aims to expand access to these therapies globally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WrVdyDF
via IFTTT

Read More

Why is healthcare AI stuck in pilot mode? UiPath has a straightforward answer

The gap between a successful AI pilot and a fully transformed healthcare operation is often wider than many organisations expect. UiPath bridges this gap by shifting the focus from simple automation to end-to-end orchestration

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uZbrVIa
via IFTTT

Read More

Roche brings 7-minute lung cancer shot to India

Roche Pharma India introduces a new injectable immunotherapy for lung cancer. This treatment takes only seven minutes, a significant reduction from hours-long infusions. It offers a less burdensome option for thousands of patients. The medicine, subcutaneous Tecentriq, is now approved for non-small cell lung cancer. This innovation aims to ease the strain on overcrowded cancer centers across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/E0hqXGM
via IFTTT

Read More

Drug regulator drafts guidelines on high-risk solvents after tainted syrup deaths in kids

India's drug regulator is creating new rules for dangerous solvents in children's medicines. This follows tragic deaths linked to contaminated cough syrups. Experts found these solvents can contain toxic impurities. The regulator is consulting with companies to assess current practices and explore safer alternatives. This action is vital after several children died from Indian-made cough syrups.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OltYzga
via IFTTT

Read More

Zydus Lifesciences close to buying US oncology drug maker for $100 to 150 million: Sources

Indian drug maker Zydus Lifesciences is close to acquiring a US company. The deal is expected to be between $100 to $150 million. This acquisition will help Zydus build its own distribution network for anti-cancer drugs in the US. The target company also has its own pipeline of biologic drugs. A deal is anticipated soon.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2KAICpO
via IFTTT

Read More

Alzheimer's a key part of Eli Lilly's India specialty medicine push, says company's country head Winselow Tucker

Eli Lilly has introduced Lormalzi in India, a pioneering treatment for Alzheimer's that specifically targets amyloid plaques, a significant contributor to the condition. Unlike previous therapies that merely alleviate symptoms, this innovative medication aims to modify the disease itself.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T78HK0t
via IFTTT

Read More

Hospitals warn Central Government Health Scheme reimbursement cap may hurt cancer treatment

A major private hospital group warns of a crisis for advanced cancer patients under the Central Government Health Scheme. A reimbursement cap on life-saving immunotherapy drugs is creating financial strain for hospitals. This policy threatens patient access to essential treatments. The association has identified nine specific drugs that are now out of reach for many beneficiaries.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4UdFNtG
via IFTTT

Read More

Eli Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity

Eli Lilly halted its obesity awareness campaign in India. The nation's drug regulator cautioned the company about potential violations. The campaign aimed to reframe obesity as a chronic disease. It featured various media without naming specific products. Lilly cited regulatory uncertainty and conflicting guidance. The regulator's advisory prohibited indirect promotion of medicines. This pause impacts a public health initiative.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oqNlEpf
via IFTTT

Read More

Lord's Mark Industries Ltd. announces AI-supported Dialysis ecosystem launch

Lord's Mark Industries Ltd. has launched an integrated dialysis ecosystem in Ahmedabad, featuring the AI-driven Renalyx Machine. This CE-certified, India-engineered system, coupled with RenalOS and Aureoon, offers a Dialysis-as-a-Service model. It aims to provide accessible, affordable, and advanced renal care by eliminating capital investment for hospitals and focusing on patient-centric, continuous treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PVAFZfB
via IFTTT

Read More

Novartis expands India role in global drug development

Novartis is focusing on innovative medicines in India. The company is expanding its role in global drug development. Early-stage research is now happening in India. Novartis plans to launch more new medicines soon. This strategy reinforces its commitment to the Indian market and its significant employee base.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NHjQ6fq
via IFTTT

Read More

Biocon arm gets Health Canada nod for fungal infection treatment injection

Biocon Pharma Ltd has secured Health Canada approval for its micafungin for injection. This medication targets serious fungal infections in adults and children. It will be used for conditions like candidemia and esophageal candidiasis. The approval also covers prophylaxis in stem cell transplant patients. This marks a significant addition to Biocon's product offerings.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/A9j4ngD
via IFTTT

Read More

Drugmakers must report safety data from launch date, not approval date: CDSCO

India's drug regulator has issued a new directive for pharmaceutical companies. Periodic Safety Update Reports for new drugs must now be submitted from the actual market launch date. This change aims to strengthen patient safety monitoring. Previously, reports were based on the regulatory approval date. The new rule ensures that real-world data from patients is included.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/grlCBG9
via IFTTT

Read More

India's hospital sector enters new growth cycle as AI and capacity expansion reshape care: Report

India's hospital sector is set for significant growth over the next decade. Demand is rising due to increased income, insurance, an aging population, and chronic diseases. Hospitals are expanding capacity to meet a critical bed shortage. Private insurance is growing, boosting revenue. This expansion offers substantial opportunities for investors and operators in the healthcare industry.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mWBKsXV
via IFTTT

Read More

EQT emerges sole bidder for OmniActive Health Technologies

Swedish investment powerhouse EQT is now leading the charge as the exclusive bidder for OmniActive Health Technologies, following the rejection of a competing offer from Temasek and Novo Holdings. Known for its robust presence in the nutraceutical industry, OmniActive is under the umbrella of TA Associates and has a strong export footprint in the United States.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/91pvszd
via IFTTT

Read More

MSD India ropes in Madhuri Dixit for cervical cancer awareness drive

US pharma major MSD has partnered with Bollywood actor Madhuri Dixit for a nationwide cervical cancer awareness program in India. The initiative aims to encourage conversations about women's preventive healthcare and prompt discussions with doctors regarding cervical cancer and its prevention. Digital films featuring Dixit have been released to amplify the campaign's reach.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EPz24lq
via IFTTT

Read More

Hantavirus outbreak on cruise ship: India monitors situation, no cases on Indian soil

The Union Health Ministry is monitoring hantavirus cases on the cruise ship MV Hondius, where three deaths and five confirmed infections have occurred. India has no domestic cases and its surveillance networks are active. The Andes strain, with limited human-to-human transmission, has been identified, and the WHO assesses the public health risk as low.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yKRBPXu
via IFTTT

Read More

India faces no immediate public health threat from hantavirus: NIV chief

Two Indian nationals aboard a cruise ship have reportedly contracted hantavirus. Indian health officials assure the public that these cases appear isolated. There is no immediate public health threat to India. Experts confirm hantavirus does not spread easily among people. India possesses adequate laboratory capacity for diagnosis. Standard rodent control and sanitation remain key preventive measures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gkVsenY
via IFTTT

Read More

Semaglutide race: Torrent grabs 38% market share

Over a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of Novo Nordisk's patent for the innovator molecule in end-March. They generated about ₹44 crore in generic semaglutide sales in April.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MRljJ4P
via IFTTT

Read More

Dr Reddy's and Nestle Health Science strengthen presence in diabetes, obesity nutrition space

Dr Reddy's teams up with Nestle Health Science to introduce Celevida GLP+, a specialized supplement crafted for those navigating the challenges of GLP-1/GIP therapy for type 2 diabetes and obesity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/shVKNgM
via IFTTT

Read More

Venus Remedies expands Latin America presence with Argentina nod for antibiotic

Venus Remedies has received approval in Argentina for its antibiotic Ceftriaxone. This marks a significant step in the company's Latin America expansion. Argentina is a key market for critical care therapies. Ceftriaxone is vital for treating serious bacterial infections. This authorization strengthens Venus Remedies' global presence and commitment to accessible anti-infective treatments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x1SmKLv
via IFTTT

Read More

Sun Pharma gets relief in trademark case from High Court

The Bombay High Court has ruled in favour of Sun Pharmaceutical Industries. The court has restrained United Biotech from using a similar trademark. Sun Pharma's 'Octride' mark is protected. The dispute involves drugs for acromegaly and carcinoid tumours. The court found Sun Pharma had a stronger claim. This decision protects Sun Pharma's reputation and goodwill.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bCipSD7
via IFTTT

Read More

Kiran Mazumdar-Shaw picks niece Claire as successor at Biocon

Biocon's founder Kiran Mazumdar-Shaw has made a groundbreaking announcement, pledging her niece Claire Mazumdar as her heir apparent. The transition plan is designed for a slow handover while Mazumdar-Shaw remains at the helm.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VeLKuyd
via IFTTT

Read More

Emcure eyes India growth, global deals amid strong demand

Emcure Pharmaceuticals is boosting domestic expansion, R&D, and manufacturing. The company is also exploring acquisition opportunities in India and internationally. New products are expected to drive significant growth. Emcure's partnership with Novo Nordisk for GLP-1 therapies and a pipeline of complex injectables will support future momentum.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pz5h9Rg
via IFTTT

Read More

The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garage

Kiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who built the company from a garage into a global biotech leader, Kiran is ensuring continuity by handing over to a science-driven leader while remaining at the helm during the transition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5aD4IzM
via IFTTT

Read More

Biocon’s Kiran Mazumdar-Shaw chooses niece Claire Mazumdar as successor: Report

Biocon founder Kiran Mazumdar-Shaw has announced her successor. Niece Claire Mazumdar will lead the company. Claire Mazumdar is the founder and CEO of Bicara Therapeutics. She holds advanced degrees and has prior industry experience. Biocon is also undergoing structural changes. The company focuses on biosimilars and integrating artificial intelligence. Other leadership transitions are also in progress across group companies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7IeS5jn
via IFTTT

Read More

Pharma exports surpass $31 billion in FY26 despite global headwinds

Indian pharmaceutical exports reached over $31 billion in FY26. March saw a significant 23% drop, primarily due to a slowdown in the United States and China. However, other markets like Africa and Oceania showed strong growth. Vaccines emerged as the fastest-growing export category. The industry is navigating challenges in key markets while exploring new growth avenues.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Cm9AgZw
via IFTTT

Read More

Carlyle acquires Knack RCM and Equalize RCM to create an AI-native, global multi-specialty healthcare RCM platform

Global investment firm Carlyle has acquired a majority stake in US healthcare revenue cycle management providers Knack RCM and EqualizeRCM. This move aims to create a global, AI-native, multi-specialty RCM platform. The combined entity will leverage AI and global delivery to enhance operational scale and client outcomes, addressing critical financial risks for healthcare providers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iHPezoQ
via IFTTT

Read More

Two separate venues for pharma industry expos in Delhi-NCR

CPHI India and PMEC India are expanding their pharmaceutical expos to two venues in Delhi-NCR. This move aims to support the rapid growth of India's pharma sector. The events will offer greater business engagement and specialized networking. CPHI India will focus on ingredients and formulations. PMEC India will showcase machinery and manufacturing technologies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Uh081QY
via IFTTT

Read More

Bombay HC backs GSK in Paxil trademark row against Shreya Life Sciences

The Indian subsidiary of the UK-based GSK PLC had urged the court to cancel the mark used by the local company in pharmaceutical and medicinal preparations. It argued that despite getting the mark more than two decades ago, Shreya Life Sciences had never used it and hence, under Section 47 of the Trade Marks Act, the registration was liable to be removed from the register of trade marks on account of non-use.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9tGdrAP
via IFTTT

Read More

Aurobindo Pharma arm CuraTeQ gets Health Canada nod for biosimilar

Aurobindo Pharma announced a significant development today. Its subsidiary, CuraTeQ Biologics, has received a compliance notice from Health Canada for its cancer drug Bevqolva. This approval marks a crucial step for the bevacizumab biosimilar. Bevqolva is used to treat various cancers. Health Canada's nod confirms its safety and efficacy. This opens new avenues for cancer treatment in Canada.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4Zb1YWw
via IFTTT

Read More

Drugs at your door: Signs of a disruption taking shape in India

India Pharmacy Retail Quick Commerce: India's medicine delivery is seeing a change. Quick-commerce apps are making it easier to buy medicines regularly. While total sales are not growing much, people are buying more wellness products. Acute care medicines are seeing fewer sales. This shift is happening as more people shop online for health items. The market is changing, not booming yet.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WA1ktfa
via IFTTT

Read More

ORS sales melt in March after govt's stricter labelling norms

India’s oral rehydration solution (ORS) market has declined after regulatory action restricted the labelling of sugary drinks as ORS, affecting pharmaceutical companies that depend on seasonal demand.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1hk20ED
via IFTTT

Read More

RPG Life Sciences bets big on API business, eyes GLP-1 entry by August-September

RPG Life Sciences is prioritizing its API business for future growth, planning a significant acquisition to scale operations. The company also aims to enter the GLP-1 weight-loss therapy market by August-September. Despite geopolitical risks, RPG Life Sciences is strategically focusing on niche, complex molecules and expanding into new therapy areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0UcztMm
via IFTTT

Read More

Weight-loss drugs may also help cut alcohol intake: Study

A new study shows GLP-1 drugs like semaglutide may help reduce heavy drinking. A trial found weekly injections cut heavy drinking days by half. This drug, also used for obesity, showed significant results in adults with alcohol use disorder. The findings could impact millions globally. Further research is ongoing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Rw2p4TY
via IFTTT

Read More

KKR invests Rs 1,750 cr in Baby Memorial Hospital

KKR, the prominent US investment firm, has committed another ₹1,750 crore to Baby Memorial Hospital, elevating their overall investment to an impressive ₹5,100 crore in just a short span of two years. This Kozhikode-centered hospital chain is poised for significant regional growth. The capital will facilitate strategic acquisitions and further expansion, now boasting nine hospitals spread across three southern states.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/neIgkx6
via IFTTT

Read More

IHH-Daiichi legal battle nears verdict on September 10

A major legal battle between IHH Healthcare and Daiichi Sankyo is reaching its climax. IHH's subsidiary, NTK, is seeking JPY 200 billion in damages. The Tokyo District Court will deliver its judgment on September 10. This ruling follows NTK's allegations of Daiichi Sankyo obstructing its acquisition of Fortis Healthcare shares.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/blz1ODJ
via IFTTT

Read More

AHH names Venkatesh Tarakkad as CFO; Ritesh Pandey moves to chief business officer role

Asia Healthcare Holdings has appointed Venkatesh Tarakkad as its new Chief Financial Officer and Head of Business Development. Tarakkad brings over three decades of experience in finance and mergers. He previously served as CFO at UpGrad. This appointment supports AHH's growth strategy. Ritesh Pandey moves to Chief Business Officer for new initiatives. AHH operates specialty healthcare brands across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JILmQ0b
via IFTTT

Read More

Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma deal

Sun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acquisition ever by an Indian pharmaceutical company. The deal values Organon at $14 per share and gives Sun Pharma a major global expansion boost, including entry into the US women’s healthcare market and stronger presence across key international regions such as China, Europe, Korea, and Latin America.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GNqISso
via IFTTT

Read More

Organon gives Sun Pharma scale and reach, but challenge lies in integration, execution

Sun Pharma has acquired Organon & Co for $11.75 billion. This deal provides Sun Pharma with expanded global scale and commercial reach. It also offers diversification into new segments like women's health and biosimilars. The acquisition is expected to strengthen Sun Pharma's position for future growth. Managing integration and debt will be key.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LVzPnCv
via IFTTT

Read More

Sun Pharma: How a small Kolkata trader became a global buyout artist

Sun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continues Shanghvi's proven strategy of acquiring companies to fuel growth and global expansion. His approach prioritizes strategic advantage and turnaround potential, as seen in past landmark deals like Ranbaxy and Taro.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fX9BkGL
via IFTTT

Read More

Robotic joint replacement surgery and insurance: The gap patients should know about

Robotic surgery offers better outcomes for knee pain patients. However, many Indians cannot access this advanced treatment due to insurance limitations. Insurers should update policies to cover robotic procedures equally with traditional ones. This will improve patient recovery and reduce long-term healthcare costs. Aligning insurance with medical progress ensures better healthcare for everyone.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rM0dKRt
via IFTTT

Read More

ET Awards: Cyrus Poonawalla reflects on SII’s mission of affordable vaccines and saving lives worldwide

Cyrus Poonawalla began Serum Institute of India in 1966 with a goal to make India self-reliant in healthcare. His vision was to provide affordable vaccines and save lives. The institute has since become a global leader, supplying vaccines to over 100 countries. It played a crucial role during the Covid-19 pandemic. Poonawalla hopes his son Adar will continue this mission.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wuhJGK2
via IFTTT

Read More

Sun Pharma to buy Organon in $11.75 billion all-cash deal

Sun Pharmaceutical Industries has agreed to acquire U.S. drugmaker Organon & Co in an all-cash deal valued at approximately $11.75 billion, including debt. The agreement stipulates Sun Pharma will purchase all outstanding Organon shares for $14.00 per share. This acquisition will grant Sun Pharma full ownership of Organon, a company focused on women's health, biosimilars, and established medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/d54ys7m
via IFTTT

Read More

ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till date

US company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai HQed company pips the consortium of EQT-Gruenthal. Sun will pay $4.5 billion for Organon’s equity and inherit $8.5 billion of its debt.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Xykj689
via IFTTT

Read More

SC asks states, UTs to prepare action plan to implement guidelines for intensive care services

The Supreme Court has directed all states and Union Territories to develop realistic action plans for implementing minimum ICU standards. An expert-prepared guideline document will be shared, with a focus on identifying and prioritizing five essential manpower and equipment requirements. A compliance and monitoring mechanism is also mandated, with a three-week deadline for a final report.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SFvyPDt
via IFTTT

Read More

Sun Pharma looks to outshine rival bids with $13 billion Organon offer

Sun Pharmaceutical is making its biggest move yet with a $13 billion offer for Organon & Co. This ambitious bid aims to transform the Indian drug giant into a global leader in branded and innovative medicines. Sun Pharma is competing with other major players for the US company. The deal, if successful, would see Organon merge with Sun Pharma.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oLTDs8N
via IFTTT

Read More

Sun Pharma wins trademark case against Navi Mumbai company

The Bombay High Court has ruled against a Navi Mumbai drugmaker. The court prohibited the use of brand names 'Absun' and 'Absun Pharma'. This decision favors Sun Pharmaceutical Industries in a decade-long trademark dispute. The court found the names deceptively similar to Sun Pharma's established marks. The ruling prevents confusion among consumers in the pharmaceutical market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/c7O6z2v
via IFTTT

Read More

Premji Invest takes stake in NewEra Hospitals to expand capacity, strengthen advanced care network

Premji Invest is backing NewEra Hospitals with a new investment. This funding will help NewEra expand its hospital capacity to 800 beds. The platform will also scale advanced specialty care across Maharashtra. NewEra currently operates three hospitals with 350 beds. The company plans to add three more hospitals in Nagpur. This expansion aims to improve access to high-complexity medical care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Y2s1A8X
via IFTTT

Read More

Different packaging, typos expose fake Mounjaro racket

Gurugram authorities uncovered a counterfeit Mounjaro operation. Police seized fake diabetes and weight loss injections valued at ₹70 lakh. The alleged mastermind, Avi Sharma, procured raw materials from China. The investigation revealed significant differences in packaging and typographical errors on the fake products. Sharma was arrested for producing these illicit drugs to increase his income.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cHDJheB
via IFTTT

Read More

Cipla gets USFDA nod for generic respiratory issues treatment inhalation aerosol

Pharma major Cipla has secured final approval from the US health regulator for its generic albuterol sulfate inhalation aerosol. This marks a significant milestone for Cipla, reinforcing its leadership in the respiratory segment. The approval enhances Cipla's US portfolio, offering a therapeutic equivalent to a key branded medication.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2C6WKwh
via IFTTT

Read More

USFDA issues Form-483 with 5 observations to Ajanta Pharma's Paithan facility

Ajanta Pharma said the US FDA has issued Form-483 with five observations after inspecting its Paithan manufacturing facility in Maharashtra from April 13–21, 2026. The company stated it will respond within the stipulated timeframe, while noting that Form-483 is issued when inspectors observe potential regulatory violations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WjGbXS1
via IFTTT

Read More

Lupin launches generic anti-diabetic tablets in US

Pharma major Lupin has launched its generic anti-diabetic medicine in the United States. The medicine is dapagliflozin and metformin hydrochloride extended-release tablets. The US Food and Drug Administration approved the drug. Lupin's product is bioequivalent to Xigduo XR. This launch offers a new treatment option for diabetic patients in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hzWucXo
via IFTTT

Read More

Govt's ammonia rule to hurt pharma cos as directive restricts sale of surplus to fertiliser firms

India’s pharmaceutical industry faces a potential raw material crunch after the government restricted surplus ammonia supply to fertiliser use. Drugmakers warn the move could disrupt API production, cause medicine shortages and impact exports, as ammonia is a critical input and alternative sourcing options remain limited.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ydy0Mio
via IFTTT

Read More

Obesity drug market to gain as Indians pop the pill and Chinese bring more

India's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, will soon be available. These pills offer a cheaper and easier alternative to injections. Experts anticipate greater patient adoption due to convenience and affordability.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3cnR9DY
via IFTTT

Read More

Counterfeit Mounjaro case: Eli Lilly issues statement after Gurugram drug racket exposed

Gurugram's law enforcement has taken a bold step by breaking up a ring creating counterfeit Mounjaro injections, with two individuals now in custody for their role in the illicit trade of diabetes and obesity medications. The illicit enterprise involved importing raw materials from China and manufacturing the injections in a private home.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5N0ywz8
via IFTTT

Read More

Bain Capital sole contender for Vitabiotics buy

TPG, EQT chose to opt out from final bids. UK’s largest nutraceutical company with operations in India, UK, China exports to 100 countries. Company was originally valued at £900 mn.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/841t3eO
via IFTTT

Read More